INmune Bio Inc reports results for the quarter ended in September 30 - Earnings Summary

Inmune Bio

01/11/2024 03:32

* INmune Bio Inc  INMB.OQ  reported a quarterly adjusted
loss
of 60 cents​​ per share for the quarter ended September 30,
lower than the same quarter last year, when the company reported
EPS of -48 cents.  The mean expectation of six analysts for the
quarter was for a loss of 50 cents per share. Wall Street
expected results to range from -55 cents to -42 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * INmune Bio Inc's reported EPS for the quarter was a loss
of 60
cents​.
    * The company reported a quarterly loss of $12.09 million.
    * INmune Bio Inc shares had risen by 10.4% this quarter and
lost 47.2% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 11.3%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for INmune Bio Inc is
20.50 
This summary was machine generated from LSEG data November 1 at
03:32 a.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2024      -0.50          -0.60          Missed
 Jun. 30 2024      -0.63          -0.50          Beat
 Mar. 31 2024      -0.53          -0.61          Missed
 Dec. 31 2023      -0.44          -0.47          Missed